Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis

Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez‐Gonzalez, Cesar, Adams, Ashok, Mathews, Joela, Turner, Benjamin P., Giovannoni, Gavin, Baker, David, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497536/
https://www.ncbi.nlm.nih.gov/pubmed/28695150
http://dx.doi.org/10.1002/acn3.410
_version_ 1783248169049522176
author Alvarez‐Gonzalez, Cesar
Adams, Ashok
Mathews, Joela
Turner, Benjamin P.
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
author_facet Alvarez‐Gonzalez, Cesar
Adams, Ashok
Mathews, Joela
Turner, Benjamin P.
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
author_sort Alvarez‐Gonzalez, Cesar
collection PubMed
description Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium‐enhancing lesions on T(1) weighted MRI brain, within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a short course of subcutaneous cladribine 60 mg led to effective suppression of inflammatory activity and partial recovery with no short‐term safety issues or adverse events.
format Online
Article
Text
id pubmed-5497536
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54975362017-07-10 Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis Alvarez‐Gonzalez, Cesar Adams, Ashok Mathews, Joela Turner, Benjamin P. Giovannoni, Gavin Baker, David Schmierer, Klaus Ann Clin Transl Neurol Brief Communications Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium‐enhancing lesions on T(1) weighted MRI brain, within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a short course of subcutaneous cladribine 60 mg led to effective suppression of inflammatory activity and partial recovery with no short‐term safety issues or adverse events. John Wiley and Sons Inc. 2017-05-17 /pmc/articles/PMC5497536/ /pubmed/28695150 http://dx.doi.org/10.1002/acn3.410 Text en © 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Alvarez‐Gonzalez, Cesar
Adams, Ashok
Mathews, Joela
Turner, Benjamin P.
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title_full Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title_fullStr Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title_full_unstemmed Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title_short Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
title_sort cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497536/
https://www.ncbi.nlm.nih.gov/pubmed/28695150
http://dx.doi.org/10.1002/acn3.410
work_keys_str_mv AT alvarezgonzalezcesar cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT adamsashok cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT mathewsjoela cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT turnerbenjaminp cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT giovannonigavin cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT bakerdavid cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis
AT schmiererklaus cladribinetotreatdiseaseexacerbationafterfingolimoddiscontinuationinprogressivemultiplesclerosis

Ejemplares similares